RT Journal Article
T1 Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
A1 Zabana, Yamile
A1 Marin-Jimenez, Ignacio
A1 Rodriguez-Lago, Iago
A1 Vera, Isabel
A1 Martin-Arranz, Maria Dolores
A1 Guerra, Ivan
A1 Gisbert, Javier P
A1 Mesonero, Francisco
A1 Benitez, Olga
A1 Taxonera, Carlos
A1 Ponferrada-Diaz, Angel
A1 Piqueras, Marta
A1 Lucendo, Alfredo J
A1 Caballol, Berta
A1 Mañosa, Miriam
A1 Martinez-Montiel, Pilar
A1 Bosca-Watts, Maia
A1 Gordillo, Jordi
A1 Bujanda, Luis
A1 Manceñido, Noemi
A1 Martinez-Perez, Teresa
A1 Lopez, Alicia
A1 Rodriguez-Gutierrez, Cristina
A1 Garcia-Lopez, Santiago
A1 Vega, Pablo
A1 Rivero, Montserrat
A1 Melcarne, Luigi
A1 Calvo, Maria
A1 Iborra, Marisa
A1 Barreiro de-Acosta, Manuel
A1 Sicilia, Beatriz
A1 Barrio, Jesus
A1 Perez, Jose Lazaro
A1 Busquets, David
A1 Perez-Martinez, Isabel
A1 Navarro-Llavat, Merce
A1 Hernandez, Vicent
A1 Arguelles-Arias, Federico
A1 Ramirez Esteso, Fernando
A1 Meijide, Susana
A1 Ramos, Laura
A1 Gomollon, Fernando
A1 Muñoz, Fernando
A1 Suris, Gerard
A1 de Zarate, Jone Ortiz
A1 Huguet, Jose Maria
A1 Llao, Jordina
A1 Garcia-Sepulcre, Mariana Fe
A1 Sierra, Monica
A1 Dura, Miguel
A1 Estrecha, Sandra
A1 Fuentes Coronel, Ana
A1 Hinojosa, Esther
A1 Olivan, Lorenzo
A1 Iglesias, Eva
A1 Gutierrez, Ana
A1 Varela, Pilar
A1 Rull, Nuria
A1 Gilabert, Pau
A1 Hernandez-Camba, Alejandro
A1 Brotons, Alicia
A1 Ginard, Daniel
A1 Sese, Eva
A1 Carpio, Daniel
A1 Aceituno, Montserrat
A1 Cabriada, Jose Luis
A1 Gonzalez-Lama, Yago
A1 Jimenez, Laura
A1 Chaparro, Maria
A1 Lopez-San Roman, Antonio
A1 Alba, Cristina
A1 Plaza-Santos, Rocio
A1 Mena, Raquel
A1 Tamarit-Sebastian, Sonsoles
A1 Ricart, Elena
A1 Calafat, Margalida
A1 Olivares, Sonsoles
A1 Navarro, Pablo
A1 Bertoletti, Federico
A1 Alonso-Galan, Horacio
A1 Pajares, Ramon
A1 Olcina, Pablo
A1 Manzano, Pamela
A1 Domenech, Eugeni
A1 Esteve, Maria
K1 COVID-19
K1 SARS-CoV-2
K1 Inflammatory bowel disease
AB We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.
PB MDPI
SN 2077-0383
YR 2022
FD 2022-01-06
LK http://hdl.handle.net/10668/21235
UL http://hdl.handle.net/10668/21235
LA en
NO Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, et al.  Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. J Clin Med. 2022 Jan 14;11(2):421
DS RISalud
RD Apr 18, 2025